慢性粒细胞白血病继发性骨髓纤维化71例诊治体会

苏丽芳; 吴芬芝; 孔宏伟; 吕红姣; 吴文萍; 王佳亨

doi:10.16766/j.cnki.issn.1674-4152.001728

慢性粒细胞白血病继发性骨髓纤维化71例诊治体会

doi: 10.16766/j.cnki.issn.1674-4152.001728

衢州市人民医院血液科，浙江衢州 324000

基金项目:

浙江省医药卫生科技计划项目 2017RC032

衢州市科技计划指导性项目 20172037

详细信息

通讯作者:
吴芬芝，E-mail：shh15463@163.com

中图分类号: R733.72 R730.5
计量
- 文章访问数: 155
- HTML全文浏览量: 62
- PDF下载量: 12
- 被引次数: 0
出版历程
- 收稿日期: 2020-10-19
- 网络出版日期: 2022-02-19

Diagnosis and treatment of 71 cases of chronic myeloid leukaemia with secondary myelofibrosis

Department of Hematology, Quzhou People's Hospital, Quzhou, Zhejiang 324000, China

摘要

摘要: 目的分析慢性粒细胞白血病(CML)合并骨髓纤维化(MF)患者的临床治疗效果及随访结果，为临床提供治疗及预后的相关数据。方法回顾性分析2014年1月—2019年6月衢州市人民医院血液科收治的71例CML合并MF患者的临床资料。CML病程3~9年，均在医院接受了系统治疗。在治疗维持或缓解期出现了进行性贫血症状、广泛性骨痛、巨脾等，符合MF(Ⅰ度)的诊断。CML患者采用格列卫治疗：餐前口服，1次/d，400~600 mg/次；或2次/d，800 mg/次；持续4周为1个疗程，共治疗4个疗程；CML合并MF患者采用芦可替尼治疗：基线血小板(PLT)在(100~200)×10⁹/L时，起始剂量为2次/d，15 mg/次；基线PLT>200×10⁹/L时，起始剂量为2次/d，20 mg/次。观察患者治疗效果及生存情况。结果治疗1周后患者疼痛、贫血症状有改善，可平卧, 脾在肋下 < 8 cm；治疗5个月后患者骨髓部分恢复造血功能，分类细胞形态大致正常，Hb≥100 g/L，WBC为(9~10)×10⁹/L，脾在肋下 < 7 cm。治疗期间患者并发症发生率为15.49%(11/71)。平均随访时间为12~63个月，9例失访(占12.68%)。19例(26.76%)存活且无复发；38例(53.52%)存活但病情复发，转为急变期，中位转为急变时间为35.8个月；5例(7.04%)因合并重症感染(2例中枢神经系统感染，3例呼吸道感染)而死亡。结论靶向药物疗法对于CML继发MF患者的治疗可以取得一定的近期疗效，病情转为急变期及生存与否等远期疗效与发生骨髓纤维化的病变情况程度有关，骨髓纤维化加重可促使病情突变或死亡。
- 慢性粒细胞白血病 /
- 骨髓纤维化 /
- 继发性 /
- 靶向药物 /
- 疗效
Abstract: Objective To analyse the clinical treatment effect and follow-up results of patients with chronic myeloid leukaemia (CML) complicated with myelofibrosis (MF) and to provide relevant data for clinical treatment and prognosis. Methods The clinical data of 71 patients with CML complicated with MF admitted in the Department of Hematology of Quzhou People's Hospital from January 2014 to June 2019 were analysed retrospectively. The course of CML was 3-9 years, and all of the patients received systematic treatment in the hospital. In the treatment maintenance or remission period, progressive anaemia, generalised bone pain and megaspleen appeared, which was consistent with the diagnosis of MF (I degree). CML: Glivec (400-600 mg/time, 1 time/day; or 800 mg/time, 2 times/day, 800 mg/time) was used in the treatment for 4 weeks/course×4 courses; CML secondary bone fibrosis: when the baseline PLT was 100-200×10⁹/L, the initial dose of lucotinib was 2 times/day, 15 mg/time; when the baseline PLT was>200×10⁹/L, the initial dose was 2 times/day, 20 mg/time. The treatment effect, follow-up results and survival rate were observed. Results Clinical treatment results: after 1 week of treatment, the symptoms of pain and anaemia were improved, and the spleen was less than 8 cm under the rib; after 5 months of treatment, the haematopoietic function of the bone marrow was partially restored, and the morphology of classified cells was generally normal; haemoglobin level was≥100 g/L; white blood cell count was 9-10×10⁹/L, and the spleen was < 7 cm under the rib. The incidence of complications was 15.49% (11/71). The average follow-up time was 12-63 months. Follow-up results: 9 cases were lost (12.68%); 19 cases survived without recurrence (26.76%); 38 cases (53.52%) survived but relapsed and turned into cataclysm. The median time of transformation was 35.8 months. Five cases (7.04%) died of severe infection (two cases of central nervous system infection and three cases of respiratory tract infection). Conclusion Targeted drug therapy can achieve a certain short-term effect in the treatment of patients with MF secondary to CML. The long-term effects such as the change of the condition to cataclysm and survival are related to the severity of myelofibrosis. The aggravation of bone marrow fibrosis can promote the change or death of the disease.
- Chronic myeloid leukaemia /
- Myelofibrosis /
- Secondary /
- Targeted drugs /
- Curative effect

HTML全文

参考文献(24)

[1]	许会静. ARF6促进人慢性粒细胞白血病K562细胞增殖和耐药的分子机制研究[D]. 长春: 吉林大学, 2014.
[2]	金洁, 杜欣, 周道斌, 等. JAK抑制剂芦可替尼治疗中国骨髓纤维化患者的疗效和安全性: A2202随访一年结果[J]. 中华血液学杂志, 2016, 37(10): 858-863. doi: 10.3760/cma.j.issn.0253-2727.2016.10.007
[3]	李慧, 申徐良, 李琦. 芦可替尼治疗骨髓纤维化患者的有效性和安全性的Meta分析[J]. 中国新药与临床杂志, 2018, 37(10): 591-600. https://www.cnki.com.cn/Article/CJFDTOTAL-XYYL201810015.htm
[4]	PIATEK C I, VERGARA-LLURI M E, PULLARKAT V, et al. Autoimmune myelofibrosis: clinical features, course, and outcome[J]. Acta Haematol, 2017, 138(3): 129-137. doi: 10.1159/000479103
[5]	陈莉莉. Meta分析芦可替尼对骨髓增殖性肿瘤的临床疗效和安全性及福建省52例骨髓纤维化患者的临床资料[D]. 福州: 福建医科大学, 2019.
[6]	GUPTA V, HARRISON C, HEXNER E O, et al. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies[J]. Haematologica, 2016, 101(12): e482-e484. doi: 10.3324/haematol.2016.151449
[7]	张之南. 血液病诊断及疗效标准[M]. 2版. 北京: 科学出版社, 1998: 22-24.
[8]	黄梓伦. 慢粒白血病与特发性骨髓纤维化: 骨髓活检的诊断问题[J]. 国际输血及血液学杂志, 1978, 1(1): 102. https://www.cnki.com.cn/Article/CJFDTOTAL-GWSX197801045.htm
[9]	郑文帅, 管立勋, 程龙灿, 等. 芦可替尼治疗慢性中性粒细胞白血病二例[J]. 中华肿瘤杂志, 2020, 42(2): 113-114. doi: 10.3760/cma.j.issn.0253-3766.2020.02.005
[10]	鄢平平. 国产伊马替尼与格列卫治疗慢性髓系白血病慢性期临床初步观察及文献资料复习[D]. 南昌: 南昌大学, 2017.
[11]	徐泽锋, 秦铁军, 张宏丽, 等. 芦可替尼联合泼尼松、沙利度胺和达那唑治疗骨髓纤维化的探索性研究[J]. 中华血液学杂志, 2019, 40(1): 24-28.
[12]	吴丹阳. 国产甲磺酸伊马替尼昕维与格列卫治疗慢性粒细胞白血病疗效及安全性比较[D]. 沈阳: 中国医科大学, 2017.
[13]	徐海婵, 张红宇, 庞丽萍, 等. 国产伊马替尼与格列卫对初诊慢性髓系白血病慢性期患者疗效及BAFF和APRIL水平的影响比较[J]. 包头医学院学报, 2019, 35(3): 36-37. https://www.cnki.com.cn/Article/CJFDTOTAL-BTYX201903015.htm
[14]	龙君. 对比研究骨髓涂片及骨髓活检在血液病诊断中的应用价值[J]. 中外医学研究, 2018, 16(5): 84-85. https://www.cnki.com.cn/Article/CJFDTOTAL-YJZY201805043.htm
[15]	孙乾, 闫志凌, 徐开林. 慢性髓细胞白血病的酪氨酸激酶抑制剂耐药机制[J]. 国际输血及血液学杂志, 2017, 40(5): 413-417. doi: 10.3760/cma.j.issn.1673-419X.2017.05.008
[16]	徐泽锋, 秦铁军, 张宏丽, 等. 芦可替尼联合泼尼松、沙利度胺和达那唑治疗骨髓纤维化的探索性研究[J]. 中华血液学杂志, 2019, 40(1): 24-28.
[17]	吴艺, 程志, 石琳, 等. IFN-α对慢性髓系白血病患者血清中细胞因子的影响[J]. 中国实验血液学杂志, 2017, 25(1): 99-103. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201701021.htm
[18]	史殷雪, 张晓辉, 许兰平, 等. 化疗联合供者淋巴细胞输注对异基因造血干细胞移植后微小残留病阳性患者慢性移植物抗宿主病及预后的影响[J]. 中华血液学杂志, 2019, 40(9): 713-714, 719.
[19]	葛岩, 胡晓丽, 郝东升, 等. 格列卫治疗慢性粒细胞白血病各期疗效观察[J]. 中外女性健康研究, 2015, 15(10): 213-214. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYZ201207014.htm
[20]	刘虹, 毛敏, 王晓敏, 等. microRNA-181b在慢性淋巴细胞白血病患者中的表达及其预后意义[J]. 中华全科医学, 2018, 16(11): 1779-1783. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201811004.htm
[21]	张震东, 曾庆曙, 倪静. 慢性粒细胞白血病合并骨髓纤维化患者疗效的观察[J]. 临床血液学杂志, 2019, 32(1): 20-23. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXZ201901006.htm
[22]	金洁, 杜欣, 周道斌, 等. JAK抑制剂芦可替尼治疗中国骨髓纤维化患者的疗效和安全性: A2202随访一年结果[J]. 中华血液学杂志, 2016, 37(10): 858-863. doi: 10.3760/cma.j.issn.0253-2727.2016.10.007
[23]	朱晓琼, 黄健. 芦可替尼治疗骨髓纤维化的剂量优化及进展[J]. 临床血液学杂志, 2018, 31(6): 828-832. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXZ201811004.htm
[24]	陈霏, 胡英伟, 杨红, 等. 慢性粒细胞白血病伴JAK2基因突变急变为急性巨核细胞白血病1例报道[J]. 检验医学, 2019, 34(5): 476-478. doi: 10.3969/j.issn.1673-8640.2019.05.021